# A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

> **NCT04946305** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 89 (actual)

## Conditions studied

- Somatostatin Receptor-positive GEP-NET

## Interventions

- **OTHER:** Lutathera

## Key facts

- **NCT ID:** NCT04946305
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-10
- **Primary completion:** 2024-07-08
- **Final completion:** 2024-07-08
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04946305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04946305, "A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04946305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*